Access to Elranatamab for Multiple Myeloma Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, single-arm study providing post-trial access to elranatamab for participants with Multiple Myeloma who have previously benefited from this treatment in earlier studies. Participants will continue receiving elranatamab until their disease progresses, they experience unacceptable side effects, withdraw consent, or the drug becomes commercially available in their country. The study aims to ensure ongoing treatment for those who have shown clinical benefit from elranatamab.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants must agree to follow the reproductive criteria as outlined in the protocol
* Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).

Exclusion Criteria:

* Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
* Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.

Where it's running

• UCI Health - Irvine Infusion Pharmacy ACC
  Irvine, California, United States Recruiting
• UC Irvine Health
  Orange, California, United States Recruiting
• UCI Health
  Orange, California, United States Recruiting
• UCHealth Poudre Valley Hospital
  Fort Collins, Colorado, United States Recruiting
• UCHealth Harmony
  Fort Collins, Colorado, United States Recruiting
• UCHealth Greeley Hospital
  Greeley, Colorado, United States Recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Elranatamab given as outpatient in relapsed or refractory multiple myeloma

  This study tests a bispecific antibody called elranatamab, given in an outpatient setting to adults with relapsed or refractory multiple myeloma who have had prior therapies.

  Recruiting at 6 sites Phase 2 SCRI Development Innovations, LLC · Denver, Colorado and 5 other locations · NCT07637578

• Elranatamab plus cyclophosphamide for relapsed/refractory multiple myeloma with high-risk features

  This will test whether adding cyclophosphamide to elranatamab helps people with relapsed or refractory multiple myeloma who have risk factors that might make elranatamab alone less effective.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07454382

• Elranatamab with lenalidomide and dexamethasone for newly diagnosed multiple myeloma.

  This trial will test whether adding elranatamab to lenalidomide and dexamethasone helps people newly diagnosed with multiple myeloma.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06997081

• Mezigdomide plus elranatamab for relapsed or refractory multiple myeloma

  This test tries adding mezigdomide to elranatamab (with dexamethasone) to see if it is safe and can help adults with relapsed or refractory multiple myeloma who have had 1–4 prior treatments (eligibility differs by phase).

  Recruiting at 20 sites Phase 1/2 Celgene · Birmingham, Alabama and 21 other locations · NCT06988488

• Personalized dendritic cell–myeloma fusion vaccine combined with elranatamab for relapsed or refractory multiple myeloma

  This will try a personalized dendritic cell–myeloma fusion vaccine given with elranatamab in people with relapsed or refractory multiple myeloma.

  Recruiting at 2 sites Phase 1 Beth Israel Deaconess Medical Center · Boston, Massachusetts and 1 other locations · NCT06799026

• Evaluating elranatamab for treating relapsed or refractory multiple myeloma

  This study is testing a new treatment called elranatamab to see if it can help people with relapsed or refractory multiple myeloma who have already tried other therapies.

  Recruiting Phase 2 University of California, San Diego · La Jolla, California · NCT06711705

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.